XOMA Royalty Faces Fiduciary Duty Probe Over $739M Ligand Acquisition

The Schall Law Firm has launched an investigation into potential breaches of fiduciary duty by the board and management of XOMA Royalty Corporation ($XOMA) in connection with the company's $739 million acquisition by Ligand Pharmaceuticals ($LGND). Shareholders are now being invited to participate in the investigation, which seeks to determine whether company leadership acted in the best interests of investors during the transaction negotiations and approval process.

Investigation Details and Scope

The legal inquiry centers on whether XOMA Royalty Corporation's board and management fulfilled their fiduciary obligations to shareholders regarding the $739 million deal with Ligand Pharmaceuticals. Fiduciary duty investigations of this nature typically examine several critical areas:

• Valuation analysis: Whether the acquisition price adequately reflected the company's true value and future earning potential
• Process integrity: Whether the board conducted a thorough, arm's-length negotiation process
• Conflict of interest: Whether any board members or executives had undisclosed conflicts that influenced their decision-making
• Alternative transactions: Whether the board properly explored other strategic options before accepting Ligand's offer
• Disclosure accuracy: Whether shareholders received complete and accurate information about the transaction terms and rationale

The Schall Law Firm is actively seeking shareholders who believe they suffered damages as a result of potential breaches of duty. By participating in the investigation, shareholders can provide evidence and testimony that may support claims against company leadership. This type of class-action investigation frequently leads to settlements or recoveries for affected investors.

Market Context and Industry Backdrop

The investigation arrives during a period of significant consolidation activity within the pharmaceutical and royalty-based business sectors. XOMA Royalty Corporation operates a unique business model focused on acquiring and managing royalty streams from biopharmaceutical companies—a strategy that has attracted considerable acquisition interest from larger pharmaceutical firms seeking to diversify revenue sources.

Ligand Pharmaceuticals, a prominent player in the specialty pharmaceutical market, has pursued an acquisition strategy centered on expanding its intellectual property portfolio and recurring revenue streams. The $739 million acquisition represents a strategic move to integrate XOMA's royalty assets into Ligand's broader portfolio management strategy.

Investor concerns about acquisition fairness have become increasingly common in recent years, particularly when:

• Smaller public companies are acquired by significantly larger competitors with greater negotiating leverage
• Royalty-based businesses are involved, given the complexity of valuing future cash flow streams
• Board composition includes insiders or individuals with potential conflicts of interest
• Market conditions have created pressure for management to accept acquisition offers

The fiduciary duty investigation framework has proven effective in protecting shareholder interests across various industries, with numerous settlements and jury verdicts resulting in substantial recoveries for affected investors over the past decade.

Investor Implications and Strategic Considerations

For shareholders of XOMA Royalty Corporation, this investigation presents both risks and potential opportunities. Those who purchased shares before the acquisition announcement at prices significantly lower than Ligand's offer price may have grounds for damages claims. The investigation could result in:

Potential Outcomes:

• Settlement negotiations between plaintiff shareholders and company defendants
• Price adjustments to the acquisition terms if substantive fiduciary breaches are demonstrated
• Monetary recoveries for investors who held shares during the relevant period
• Strengthened governance standards for future transactions involving XOMA or similarly structured companies

For Ligand Pharmaceuticals shareholders, the investigation introduces litigation risk that could affect the integration timeline or ultimate cost of the acquisition. If significant breaches are found, courts may require enhanced disclosures or modifications to the transaction structure.

Broader market implications suggest that investors should heighten scrutiny of special committee processes and fairness opinions in similar acquisition scenarios. The investigation reinforces the importance of:

• Independent valuations by qualified financial advisors
• Transparent board deliberation and documented decision-making processes
• Fair-dealing principles in negotiations between parties with disparate bargaining power
• Shareholder communication that fully discloses material information and transaction rationale

Looking Forward

The Schall Law Firm's investigation into XOMA Royalty Corporation's $739 million acquisition by Ligand Pharmaceuticals represents an important mechanism for protecting shareholder rights during significant corporate transactions. As consolidation activity continues across the pharmaceutical and specialty biotech sectors, such investigations serve as a critical check on board accountability and management conduct.

Shareholders who held XOMA stock during the relevant period and believe the acquisition price undervalued the company should carefully consider participating in the investigation. The process typically remains confidential and shareholder-friendly, with legal representation provided on a contingency basis in many cases.

The coming weeks and months will determine whether the investigation uncovers substantive evidence of fiduciary breaches. Regardless of the ultimate outcome, the inquiry underscores an evolving expectation that corporate boards must demonstrate rigorous, arm's-length negotiation processes and genuine commitment to maximizing shareholder value in major transactions. For Ligand Pharmaceuticals and other acquirers in the sector, the investigation serves as a reminder that acquisition strategy must be coupled with transparent, defensible governance practices.